Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort.
about
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment optionsAntimicrobial resistance in Acinetobacter baumannii: From bench to bedsideWhat's new in multidrug-resistant pathogens in the ICU?Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill PatientsAnticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter InfectionsUpdate on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections.Impact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia.Mechanisms of antimicrobial resistance in Gram-negative bacilli.Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.Synergy and mechanism of action of α-mangostin and ceftazidime against ceftazidime-resistant Acinetobacter baumannii.Colistin: still a lifesaver for the 21st century?Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis.Tigecycline: Alone or in combination?Task force on management and prevention of Acinetobacter baumannii infections in the ICU.Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.Combination therapy for extensively-drug resistant gram-negative bacteria.Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis.Enhancing Whole Phage Therapy and Their Derived Antimicrobial Enzymes through Complex Formulation.Epidemiology and treatment of antimicrobialresistant gram-negative bacteria in Korea.Differential characteristics of Acinetobacter baumannii colonization and infection: risk factors, clinical picture, and mortality.
P2860
Q27015109-08BFF5F6-DA8D-4EEB-9789-6E366FF5583CQ27024893-E223C2B2-8AF3-43F1-979D-7A9DF6A15BF8Q28071346-0F230E49-4166-4066-AFE4-3DE876B43D80Q28550492-C22CFCFB-1E08-4CB8-9277-0912F6A7ED46Q33732524-8A073372-C120-43D7-80BE-EB097EEF4279Q34168292-EB96359D-01AE-4D8C-B9A5-20C34EBBDE47Q35746258-FAB62AD4-A0DD-44EC-8152-85BCF887D35AQ35935319-26D6D37D-92DD-4C73-B6BC-07CC2FD0871DQ38286351-42DBDE73-6C70-41DB-A249-B125003318A1Q38384662-3632D583-B181-4F19-81CA-6DCE49EF578BQ38416932-9BA6D760-4C97-4F3A-AD11-E53F5914FFAFQ38629276-5A82C20B-EDE3-4476-BCB4-220031BA46F7Q38940249-78738124-3AE2-46C9-BEDB-36080FC7F497Q38953618-BAB88ABF-4BA4-4824-A6D4-A92F9A81A530Q39916184-EE2D3589-5F42-4ACD-8250-D776DFF47213Q40965515-F9838E0C-608D-44D8-A4E6-293BE6A56A21Q47661746-53E105A0-E0BB-46C1-B23E-8B432B22131EQ47819621-0C11AE74-1267-4217-98A8-984CBDAB93D0Q50082670-20068E2A-A474-483C-9878-87E8B246C9D1Q52315864-0AAEFC85-816B-4164-A108-EBA982087756Q53704499-B4B85FA7-66A4-47C2-A6E0-4CAF06A595ECQ55378575-A0A7385B-E46E-41E1-9171-CF56CF25E36A
P2860
Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Monotherapy versus combination ...... ulticentre prospective cohort.
@en
Monotherapy versus combination ...... ulticentre prospective cohort.
@nl
type
label
Monotherapy versus combination ...... ulticentre prospective cohort.
@en
Monotherapy versus combination ...... ulticentre prospective cohort.
@nl
prefLabel
Monotherapy versus combination ...... ulticentre prospective cohort.
@en
Monotherapy versus combination ...... ulticentre prospective cohort.
@nl
P2093
P2860
P50
P921
P356
P1476
Monotherapy versus combination ...... multicentre prospective cohort
@en
P2093
F Fernández-Cuenca
GEIH/REIPI-Ab2010 Group
J Garnacho-Montero
J M Cisneros
P2860
P304
P356
10.1093/JAC/DKU233
P407
P50
P577
2014-06-25T00:00:00Z